SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-22-004948
Filing Date
2022-07-14
Accepted
2022-07-14 08:02:47
Documents
34
Period of Report
2022-05-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cnbx_i10q-5312022.htm   iXBRL 10-Q 429596
2 CERTIFICATIONS cnbx_ex3101.htm EX-31.1 10140
3 CERTIFICATIONS cnbx_ex3102.htm EX-31.2 10313
4 CERTIFICATIONS cnbx_ex3201.htm EX-32.1 5077
5 CERTIFICATIONS cnbx_ex3202.htm EX-32.2 4880
  Complete submission text file 0001683168-22-004948.txt   1659844

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20220531.xsd EX-101.SCH 12515
7 XBRL CALCULATION FILE cnbx-20220531_cal.xml EX-101.CAL 28675
8 XBRL DEFINITION FILE cnbx-20220531_def.xml EX-101.DEF 16863
9 XBRL LABEL FILE cnbx-20220531_lab.xml EX-101.LAB 122476
10 XBRL PRESENTATION FILE cnbx-20220531_pre.xml EX-101.PRE 88717
28 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q-5312022_htm.xml XML 124427
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

IRS No.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 221082231
SIC: 2834 Pharmaceutical Preparations